Full Breakdown
Tate & Lyle to be acquired by US ingredient group Ingredion in £2.7 bn cash deal
6/9/2026, 12:31:57 AM
Deal Summary
On 8 June 2026 Ingredion announced an all-cash acquisition of UK-listed Tate & Lyle. Shareholders will receive 595 pence per share in cash plus dividend entitlements of up to 20 pence, for a total of 615 pence per share. The offer represents a premium of roughly 57 %–64 % over the pre-talk price and values the combined entity at an enterprise value of about £3.8 bn, including debt.
Background
Tate & Lyle traces its origins to rival 19th-century sugar refineries that merged in 1921. After selling its historic sugar business in 2010, the company refocused on artificial sweeteners (e.g., Splenda) and specialty food ingredients. A 2024 purchase of CP Kelco expanded its portfolio into gums and pectins. Weak consumer demand, a 10 % drop in first-half profit in 2025 and a prolonged share-price decline left the firm vulnerable to takeover interest.
Key Players
- Tate & Lyle – FTSE 250 listed, ~5 000 employees worldwide (?200 in the UK).
- Ingredion – Chicago-based, ~11 000–12 000 employees, 2025 revenue $7.22 bn.
- David Hearn – Chair, Tate & Lyle.
- Jim Zallie – Chairman and CEO, Ingredion.
Financial & Operational Impact
The cash component of 595 pence per share plus up to 20 pence dividends yields a total consideration of 615 pence per share. Combined annual revenue of the merged group is projected at about US$9.9 bn (£7.4 bn) with adjusted profit of US$1.8 bn. Workforce totals will rise to roughly 16 000 employees; the deal foresees cost synergies of US$130 m by 2030 and annual savings of US$97.5 m by the same date. A material reduction of up to 3 % of the combined staff—approximately 475–480 roles—is anticipated.
Why It Matters
The transaction ends Tate & Lyle’s 87-year presence on the London Stock Exchange, making it the last survivor of the original FT-30 index. It reflects a broader wave of foreign takeovers of UK-listed firms in 2026 and creates one of the world’s largest specialty-ingredients platforms, positioned to meet rising demand for lower-sugar, higher-protein and clean-label solutions driven by health-focused consumer trends and the impact of GLP-1 weight-loss drugs.
Official Statements
Tate & Lyle’s board recommended the offer as an “attractive opportunity” for shareholders and described Ingredion as an “excellent steward.” A joint statement said any workforce reduction would be undertaken to “combine the strengths and capabilities of both businesses.” Ingredion emphasized that the merger will produce a “global leader in ingredient solutions” with expanded geographic reach and innovation capacity.
Criticism & Opposition
Analysts highlighted the risk of up to 480 job cuts and uncertainty over the future of the UK headquarters. Industry commentary framed the deal as a “blow to the London market” amid a series of high-profile foreign bids on domestic companies.
Conflicting Reports
Sources differ on the exact premium (57 % vs 64 % vs 71 %), the enterprise-value figure (£3.7 bn vs £3.8 bn) and the projected cost-saving amount (US$130 m vs US$97.5 m annually). Reported job-cut numbers range from 475 to 480 positions.
Verbatim Quotes
- “Combining Ingredion and Tate & Lyle’s complementary portfolios creates a global leader in ingredient solutions with the expertise and geographic reach to help shape the future of food.” — Jim Zallie, Chairman and CEO, Ingredion
- “We believe the next chapter with Ingredion will create a business with even greater potential, greater scale, and increased investment in innovation in support of customers.” — David Hearn, Chair, Tate & Lyle
- “Any such workforce reduction would be implemented with the aim of combining the strengths and capabilities of both businesses,” — Joint statement, Tate & Lyle and Ingredion
- “Ingredion does not intend to make any changes to Tate & Lyle’s overall workforce, other than in certain corporate, manufacturing and support functions where there is overlap with existing roles and operations within the Ingredion Group.” — Ingredion spokesperson
What’s Next
The proposal now requires shareholder approval and clearance from the UK Competition and Markets Authority. Ingredion aims to complete the acquisition in the second half of 2027, after which a review of overlapping operations and any redundancies will commence.
